Abstract
The treatment of bone defects is still an intractable clinical problem, despite the fact that numerous treatments are currently available. In recent decades, bone engineering scaffolds have become a promising tool to fill in the defect sites and remedy the deficiencies of bone grafts. By virtue of bone formation, vascular growth, and inflammation modulation, the combination of bone engineering scaffolds with cell-based and cell-free therapy is widely used in bone defect repair. As a key element of cell-free therapy, exosomes with bioactive molecules overcome the deficiencies of cell-based therapy and promote bone tissue regeneration via the potential of osteogenesis, angiogenesis, and inflammation modulation. Hence, this review aimed at overviewing the bone defect microenvironment and healing mechanism, summarizing current advances in bone engineering scaffolds and exosomes in bone defects to probe for future applications.
Introduction
Bone is one of the important organs of the musculoskeletal system, which has load-bearing abilities and can perform locomotion as well as protect the internal organs. When suffering from high-energy trauma, nonunion, osteomyelitis, and tumor resection, loss of bone tissues will result in bone defects (Ma et al., 2021). Bone tissues are constantly remodeled and have better self-repair and regeneration ability, which allows the damaged bone tissues to fully recover to pre-injury integrity and mechanical properties (Majidinia et al., 2018). On the contrary, when the defects exceed the regeneration ability due to insufficient blood supply, local infection, drug side effects, malnutrition, etc., it will be difficult for large-sized bone defects to return to normal and seriously affect the patients’ motor function and life quality, which necessitates extra clinical treatments (Nauth et al., 2018).
For bone defects, the aim of rehabilitation is to recover the mechanical and functional integrity of the structure, so bone grafts and bone graft substitutes become suitable choices, which are widely explored for a better therapeutic effect (Li S. et al., 2021). The current available grafts include autologous bone grafts, allogeneic bone grafts, heterogenous bone grafts, and synthetic grafts, as well as cell-based therapy and cell-free therapy such as stem cells, bioactive factors, and extracellular vesicles (Baldwin et al., 2019; Wang and Yeung, 2017). Whether autologous bones or allogeneic and heterogenous bones, all have limitations for the treatment of bone defects, which make it difficult to meet the clinical demands (Schmidt, 2021). Consequently, it is urgent to develop alternative synthetic graft substitutes such as bone engineering scaffolds. An ideal bone engineering scaffold should meet the following criteria: excellent biocompatibility, biodegradability, osteoconduction, osteoinduction, and osteogenesis (Turnbull et al., 2018). To date, inorganic components, natural polymers, synthetic polymers, and metals, such as hydroxyapatite, collagen, poly(lactic acid), black phosphorus, and magnesium alloys, have been utilized in bone tissue engineering scaffolds (Amiryaghoubi et al., 2020; Bharadwaz and Jayasuriya, 2020; Zhang B. et al., 2021).
To fill in the bone defect sites and achieve desired therapeutic outcomes, bone engineering scaffolds are often integrated with stem cells, bioactive molecules, and extracellular vesicles (Brennan et al., 2020). Though bone engineering scaffolds provide stem cells with a platform for cell adhesion, migration, proliferation, and differentiation, the stem cells are also not ideal supplementary materials due to low survival rate, immunological rejection, tumorigenesis, and microthrombosis (Brennan et al., 2020). The extracellular vesicles, such as exosomes, have been proven to present parental cells and deliver bioactive molecules (e.g., nucleic acids, proteins, lipids, and metabolites), thus having the ability of osteogenesis, angiogenesis, and inflammation modulation, which promise to be desirable components combining with bone engineering scaffolds to repair bone defects (Huber et al., 2022; Li et al., 2020; Liu et al., 2018). The applications of exosomes and bone engineering scaffolds are still to be further researched, and there remain some problems to be solved. Therefore, this review will first focus on the bone defect microenvironment and bone healing mechanism. Based on this, we will discuss current treatments of bone defects and especially highlight bone engineering scaffolds and cell-free therapy. Then we will summarize the applications of exosomes and bone engineering scaffolds in bone defects. The potential problems and improvements to optimize exosome-integrated bone engineering scaffolds are also discussed.
Bone Defect Microenvironment and Bone Healing Mechanism
The bone tissue structures are composed of cortical bone and cancellous bone (Buck and Dumanian, 2012). The cortical bone, consisting of osteons, acts as a supporter due to high mechanical strength. The cancellous bone, a porous structure, is composed of trabecular bones and bone marrows, which is the harbor of hematopoiesis and bone metabolism (Buck and Dumanian, 2012). In general, bone tissues are constantly in the state of dynamic absorption and remodeling, making it possible for bone tissues to adapt to growth, development, and dynamic mechanic load (Oftadeh et al., 2015). However, the normal function of the bone depends on its structural and compositional integrity, and bone regeneration depends on an ideal microenvironment. For a critical-sized defect, a bone engineering scaffold will provide the damaged bones with mechanical support and a microenvironment favorable for regeneration (Roseti et al., 2017). Therefore, an in-depth understanding of the bone defect microenvironment will provide clues for developing a better bone engineering scaffold system and promoting bone regeneration.
Bone Defect Microenvironment
The bone defect microenvironment refers to the dynamic composition and cross-interactions of various cells and molecules in the bone defect sites (Figure 1). The microenvironment is extremely complex. On one hand, it spans the various stages of bone healing in terms of time, including the inflammation stage, bone formation stage, and remodeling stage (Oryan et al., 2015). On the other hand, its composition includes a wide variety of cells, such as mesenchymal stem cells (MSCs), hematopoietic stem cells, immune cells, endothelial cells, osteoblasts and osteoclasts, and various bioactive factors, such as receptor activator of nuclear factor-kappa B ligand (RANKL), platelet-derived growth factor (PDGF), bone morphogenetic proteins (BMPs), and interferon-gamma (IFN-γ), which engage in osteogenesis, angiogenesis, and inflammation modulation (Safari et al., 2021; Zhou et al., 2021). Detailed summaries and discussions have been reviewed by Zhu et al. (2021). In the meanwhile, a recent single-cell sequencing study revealed that skeletal muscle-derived mesenchymal progenitors also engage in bone repair, which will explain why adjacent tissues also matter (Julien et al., 2021). In addition, Zhang H. et al. (2021) suggest that B cells are key regulators of bone healing in the bone marrow microenvironment due to the opposite pattern between B cells and bone formation and resorption activities. Considering the fact that outcomes of bone defect healing are uncertain under the influence of different risk factors, such as age, nutritional status, and contamination degree (Nicholson et al., 2021), we suspected that differences in the bone defect microenvironment may contribute to it. Therefore, further research studies on the bone defect microenvironment will help to explain the bone healing mechanism and pathogenesis of nonunion and delayed union, providing novel ideas and more personalized strategies for clinical practice.
FIGURE 1
Bone Healing Mechanism
The defects sites initiate a cellular cascade to repair injury and promote regeneration shortly after the occurrence of bone defects. These cells participate in several continuous events, including hematoma formation, inflammatory reaction, fibrous callus formation, intramembranous ossification, endochondral ossification, and bone remodeling, which accompany an orderly cascade of anabolism and catabolism (Li et al., 2019). Specifically, blood clots in the damaged areas and immune cells migrate to remove the necrotic components. Next, recruited fibroblasts, osteoprogenitor cells, and MSCs proliferate and differentiate to form a fibrous tissue, followed by intramembranous and endochondral ossification. In the final stage, the new bone tissues are constantly absorbed and remodeled under mechanical forces, forming an orderly bone structure and returning to normal function (Kalfas, 2001; Zhu et al., 2021). Intramembranous ossification means that MSCs migrate and proliferate to form condensation, differentiate into osteoblasts, and secrete collagen, followed by vascular ingrowth and cortical bone and cancellous bone formation (Percival and Richtsmeier, 2013). Endochondral ossification means that MSCs differentiate into chondrocytes and secrete collagen matrix, followed by vascular ingrowth and cartilage degradation, finally forming the primary ossification center and secondary ossification center, and forming mature bone structure (Mackie et al., 2011). In addition, many other cytokines are also involved in the process of bone healing (Zhu et al., 2021). Although bone tissues have the remarkable ability of healing, bone defects still do not return to normal when the defect ranges exceed the critical-sized bone defect, which means loss of a length exceeding 2–2.5 times the diameter of the damaged bone (Wiese and Pape, 2010). This will overwhelm the ability of bone regeneration because of mechanical instability and biological disadvantage, indicated by poor vasculature, bone nonunion, and pseudarthrosis, which requires clinical treatments to support mechanical stability and a suitable microenvironment so as to achieve functional reconstruction (Elliott et al., 2016). Consequently, the in-depth understanding of bone biology, bone defect microenvironment, and bone healing mechanisms will provide references for the design and application of bone engineering scaffolds with bioactive factors.
Current Treatments of Bone Defects
The interventions of large segmental bone defects usually require repair and reconstruction techniques (Nauth et al., 2018). However, the treatments of bone defects remain a striking challenge to date because of the shortage of autologous bone tissues and the lack of ideal graft materials (Wang and Yeung, 2017). With the development of materials science and engineering technology, the combination of advanced manufacturing technology with ideal materials, bone-implant interface modification, and the supplement of bioactive factors provides a broad space for the treatment of bone defects (Tovar et al., 2018; Turnbull et al., 2018).
Bone Graft Reconstruction
Bone grafts include autologous bone grafts, allogeneic bone grafts, and heterogenous bone grafts, all of which have different characteristics (Shang et al., 2021). Autologous bone grafts have fresh cortical and cancellous bone tissues containing viable osteoblasts, osteocytes, MSCs, and growth factors, thus possessing good osteoconductive, osteoinductive, and osteogenic properties. Owing to the maintenance of osteogenic potential and basis, autologous bone grafts are considered as the gold standard in the treatment of bone defects (Baldwin et al., 2019). However, some shortcomings restrict its application, for example, limited availability, donor site infection, hematoma, and pain (Schmidt, 2021). Allogeneic bone grafts refer to bone tissues from other individuals, which are immunogenic and have the risk of the spread of potential pathogens (Wang and Yeung, 2017). Therefore, processed and modified allogeneic bones overcome their own shortcomings and become the most available grafts, considered the best alternative to autografts. Demineralized bone matrix (DBM) is a highly processed allogeneic graft, which is often used to fill in bone defects (Hao et al., 2022). Similarly, heterogenous bone grafts face the same concerns, such as immunogenicity and disease transference (Amiryaghoubi et al., 2020). In general, due to the aforementioned drawbacks, bone grafts may not be the optimal ones, so it is necessary to design and manufacture promising bone engineering grafts with excellent osteoconduction, osteoinduction, and osteogenesis.
Bone Graft Substitute Reconstruction
The development of bone graft substitutes aimed at simulating natural bone tissues to produce bone scaffolds with excellent capacity for osteoconduction, osteoinduction, osteogenesis, and angiogenesis (Tan et al., 2021). At present, a variety of alternative materials have been utilized for scaffold engineering, including inorganic components (e.g., hydroxyapatite, CaP cement, and ceramics), natural polymers (e.g., collagen, chitosan, alginate, and hyaluronic acid), synthetic polymers (e.g., poly(lactic-co-glycolic acid), poly(lactic acid), and poly(caprolactone)), and metals (e.g., magnesium and magnesium alloys, Zn and Zn alloys, and titanium and titanium alloys) (Table 1) (Amiryaghoubi et al., 2020). The summaries of types and manufacturing technologies have been reviewed recently (Bharadwaz and Jayasuriya, 2020; Wang and Yeung, 2017). In addition, new engineering techniques are used to solve practical application problems, for example, a microfluidic 3D printing strategy fabricates photothermal responsive channeled scaffolds, which facilitate vascular ingrowth and bone regeneration (Wang et al., 2021). In general, advances in materials science and engineering technology gradually make it possible for more bone engineering scaffolds to be used in clinical practice.
TABLE 1
| Material type | Example | Advantage | Disadvantage | References |
|---|---|---|---|---|
| Inorganic components | Hydroxyapatite, CaP cements, and ceramics | High compressive strength and low ductility | Brittleness | Gao et al. (2014) |
| Natural polymers | Collagen and chitosan | Good biocompatibility, osteoconductivity, and low immunogenicity | Degradation rate difficult to control and low mechanical stability | Ebhodaghe, (2021) |
| Synthetic polymers | Poly(lactic-co-glycolic acid) and poly(lactic acid) | Controlled degradation rate, the possibility to design or tune bone mechanical properties, plasticity, and the potential to deliver soluble molecules | Lower ability to interact with cells | Amiryaghoubi et al. (2020) |
| Metals | Magnesium alloys and titanium alloys | High strength and modulus, good biocompatibility | Degradation and hydrogen generation | Zhang et al. (2021c) |
| Ideal scaffold | Biocompatible, non-toxic, bioresorbable, biodegradable, non-immunogenic, bioactive, biomimetic, customized shape, high porosity, and mechanical properties | Roseti et al. (2017) | ||
Brief comparison of bone engineering scaffold materials.
Masquelet’s Induced Membrane Technique
Masquelet’s induced membrane technique is a two-stage surgical procedure to treat segmental bone defects, which was first reported in the mid-1980s (Alford et al., 2021). This procedure combines surgical techniques, bone healing mechanisms, and bone grafts, significantly promoting bone defect repair (Nauth et al., 2018). This procedure is divided into two stages. The first stage is to remove damaged tissue, implant a bone cement spacer, and install a fixation device, followed by waiting for formation of the surrounding foreign-body membrane. The secondary stage is to remove the spacer and fill the cavity with bone grafts or bone graft substitutes, followed by several months of healing (Alford et al., 2021). Though this procedure is promising, there are some problems to be solved, for example, time consumption, the lack of standard surgical details, and the shortage of evidence to supplement bioactive factors and optimize individual outcomes (Morelli et al., 2016).
Cell-Based Therapy and Cell-Free Therapy
Cell-based and cell-free scaffolds often combine bone engineering scaffolds with cells, cytokines, nucleic acids, or extracellular vesicles, which enhance the osteoinductive and osteogenic capacity of the scaffolds (Li et al., 2019). With multilineage differentiation potential and intrinsic properties, MSCs are the most promising stem cells being applied in bone regeneration medicine to promote wound healing, osteogenesis, and inflammation modulation (Chew et al., 2019). The advancing applications of MSCs in bone regeneration have been reviewed by Shang et al. (2021). Though relevant basic and clinical translational research studies are being carried out vigorously, cell-based therapy has some limitations, such as low viability, immune rejection reaction, tumorigenesis, and microthrombosis (Watanabe et al., 2021). Alternative options are based on the secretion and paracrine signaling of MSCs, that is, cell-free therapy; for example, growth factors, cytokines, nucleic acids, and extracellular vesicles (Zhang et al., 2022; Swanson et al., 2020). The types, time, and dosage of growth factors and cytokines supplementing scaffolds are important parameters, which depend on the stages of bone healing because the biomolecules’ interaction is pretty intricate in a spatiotemporal manner (Safari et al., 2021). More efforts have been made to achieve controlled release of cytokines, which deserves further exploration. Moreover, as an important gene regulator at the post-transcriptional level, nucleic acids are supplemented to regulate gene expression and promote osteogenesis, which usually requires a carrier to transport them into the cells (Li Z. et al., 2021). In addition, extracellular vesicles possess the inherent capacity to carry biomolecules, thus mediating molecule delivery to promote regeneration (Ramis, 2020). Extracellular vesicles, including exosomes, apoptotic bodies, and microvesicles, particularly exosomes, have been reported to recapitulate the advantageous properties of stem cells and enhance the effects of bone engineering scaffolds (Pishavar et al., 2021; Qin et al., 2016). The advancing applications of exosomes and scaffolds will be elaborated in the next section.
Applications of Bone Engineering Scaffolds With Exosomes in Bone Defects
The exosome-integrated bone engineering scaffolds synergize mechanical support and the ability of osteoconductivity, osteoinduction, and osteogenesis, which have been widely explored in bone defect animal models and achieve good therapeutic effects (Figure 2) (Wei et al., 2019). In recent years, the osteogenic property of bone engineering scaffolds has been continuously explored, and the investigation of angiogenesis has also been widely conducted (Turnbull et al., 2018).
FIGURE 2
Exosome Overview
Exosomes, originating from multivesicular bodies, are widely found in biofluids and cell mediums, which range from 30 to 150 nm in diameter (Liu A. et al., 2021). They carry nucleic acids, proteins, lipids, and metabolites, playing key roles in intercellular communication (Lu et al., 2019). It has been reported that exosomes have diagnostic and therapeutic potential in various diseases, including bone defects (Al-Sowayan et al., 2020; Furuta et al., 2016). Compared with cell-based therapy, the sources of exosomes applied in bone defects are more widespread, which is not limited to stem cells. In addition, exosome-based therapy has several benefits, such as no immunogenicity, similar functional properties to stem cells, and no risks of tumorigenesis and engineering modification (Fan et al., 2020).
Exosomes in Osteogenesis, Angiogenesis, and Inflammation Modulation in Bone Defect Microenvironment
Nucleic acids, proteins, lipids, and metabolites in exosomes engage in intercellular communication and impact the recipient cells to regulate biological functions (Escude et al., 2021). Relevant research studies show that exosomes are engulfed by surrounding target cells, such as osteoprogenitors, osteoblasts, endothelial cells, and immune cells, in the bone defect microenvironment, thereby widely participating in osteogenesis, angiogenesis, and inflammation modulation.
Exosomes and Osteogenesis
In bone regeneration, the exosomes with osteogenic potential are able to promote MSCs to increase the expression of osteogenic factors and osteogenesis-related proteins, such as RUNX2, COL1A1, OPN, and ALP (Narayanan et al., 2016). Bioactive molecules in exosomes are key mediators of osteogenesis, and several reports show that microRNA (miRNA) is an important post-transcript regulator to modulate the expression of osteogenic-related genes(Liu W.-z. et al., 2021; Yin et al., 2021). For example, the RNA-sequencing of osteogenic exosomes from human MSCs suggests that exosomes include upregulated osteogenic miRNAs (Hsa-miR-146a-5p, Hsa-miR-503-5p, Hsa-miR-483-3p, and Hsa-miR-129-5p) or downregulated anti-osteogenic miRNAs (Hsa-miR-32-5p, Hsa-miR-133a-3p, and Hsa-miR-204-5p), which activate the PI3K/Akt and MAPK signaling pathways (Zhai et al., 2020). In addition, MSC-released exosomal miR-1260a (Wu et al., 2021); miR-335 (Cao et al., 2021); miR-140 and miR-375 (Chen et al., 2019); miR-26a, miR-199a, miR-21, and miR-23a-3p (Hu et al., 2020); let-7a-5p, let-7c-5p, miR-328a-5p, and miR-31a-5p (Liu A. et al., 2021); and miR-150-5p (Jing et al., 2022) have been reported to promote osteogenesis. The exosomes promoting osteogenesis involve many pathways, such as BMP/Smad, Wnt/β-catenin, PTEN/PI3K/Akt, and Hippo signaling pathways (Cao et al., 2021; Cui et al., 2016; Hu et al., 2020; Zhang et al., 2016). There are other cell-derived exosomes promoting or inhibiting osteogenesis. For example, Li et al. (2016) showed that osteoclast-derived exosomal miR-214-3p inhibits osteogenesis and reduces bone formation. Weilner et al. (2016) reported that osteoblast-derived exosomal galectin-3 levels are positively correlated with osteoinductive potential. Qi et al. (2016) reported that human-induced pluripotent stem cell–derived MSC-released exosomes significantly promote osteogenesis and angiogenesis. Li et al. (2018) showed that human adipose stem cell–derived exosomes promote the proliferation and differentiation of MSCs. Swanson et al. (2020) found that human dental pulp stem cell–derived exosomes facilitate MSC differentiation and mineralization. Wu et al. (2020) reported that Schwann cell–derived exosomes can promote the proliferation and differentiation of MSCs. Cao et al. (2021) found that mature dendritic cell–derived exosomes enhance osteogenic differentiation of MSCs. Moreover, some studies have focused on regulating exosomes to increase their osteogenic activity, such as aptamer-functionalized exosomes, static magnetic field–treated exosomes, exosomes endowed with plasmids, genetic engineered exosomes, hypoxic environment-treated exosomes, hydrogel-assisted 3D cultured exosomes, and exosomes with fusion peptide (Li et al., 2022; Luo et al., 2019; Ma et al., 2022; Shen et al., 2022; Wu et al., 2021; Yu et al., 2022; Zha et al., 2021). In general, the treatment of exosomes increases the osteogenic ability in the bone defect microenvironment, which is beneficial for bone defect repair.
Exosomes and Angiogenesis
Adequate blood supply is an important basis for successful bone regeneration. The effects of angiogenesis mediated by exosomes have been reported, indicated by the increased expression of angiogenesis factors, tube formation, endothelial cell proliferation, and migration (Zhang J. et al., 2021). For example, Wu et al. (2022) suggested that MSC-derived exosomal miR-21 target SPRY2, promotes angiogenesis. Another report shows that miR-21 promotes angiogenesis by the miR-21/NOTCH1/DLL4 signaling axis (Zhang Y. et al., 2021). Wu et al. (2021) found that MSC-derived exosomal miR-1260a enhanced angiogenesis via the inhibition of COL4A2. Sahoo et al. (2011) showed that MSC-derived exosomes increased endothelial cell viability. Jing et al. (2022) reported that stem cells from apical papilla-derived exosomes promote angiogenesis by miR-126-5p, indicated by increased expression of VEGF and ANG-1. In addition, hypoxic condition–treated cell-derived exosomes increase the tube formation (Liu et al., 2020). Zha et al. (2021) also reported that progenitor cell–derived exosomes endowed with VEGF plasmids release the VEGF gene to promote angiogenesis (Figure 3).
FIGURE 3
Exosomes and Inflammation Modulation
Inflammatory cells and immune cells are important components of the bone defect microenvironment, and a moderate inflammatory response is imperative for bone defect repair (Lin et al., 2022). It has been reported that exosomes play a role in inflammation modulation. For example, MSC-derived exosomes can promote macrophage polarization toward the M2 phenotype and inhibit the inflammatory response, indicated by the reduced gene and protein expression of inflammatory cytokines, such as IL-6 and TNF-α (Guan et al., 2022; Jiang et al., 2021; Lu et al., 2021; Wang X. et al., 2020). Research shows that MSC-derived exosomes promote macrophage M2 polarization via the NF-κB pathway (Fan et al., 2021). In addition, Lin et al. (2022) showed that HUVEC-derived exosomes overexpressing PD-L1 bind to PD-1 on the T-cell surface, which suppresses the activation of T cells and promotes MSCs toward osteogenic differentiation because of the inhibition of overactive inflammation. Consequently, exosomes are important regulators of immune response and bone regeneration in the bone defect microenvironment.
To sum up, the role exosomes play in bone defect repair is multifaceted, including osteogenesis, angiogenesis, and inflammation regulation, which supplement each other. Specifically, the effects of exosomes in the bone defect microenvironment are due to 1) promotion of osteogenic differentiation of the target cells, 2) promotion of angiogenesis for providing an optimal bone regeneration niche, and 3) inflammation modulation for maintaining a moderate immune response. Thus, the exosome is a kind of promising cell-free therapeutic material to repair bone defects.
Exosome-Integrated Bone Engineering Scaffolds In Vivo Bone Defects
The treatment of exosome-integrated bone engineering scaffolds provides not only mechanical support for bone defects but a suitable microenvironment for bone regeneration. The research studies on bone engineering scaffolds for bone defects primarily focus on the components, characteristics, interface modification, and the release of bioactive factors (Gandolfi et al., 2020; Nikhil and Kumar, 2022; Zhang et al., 2018). Although most of the scaffolds have been proven to possess the definite potential of osteogenesis, the supplement of exosomes can enhance their performance (Figure 4) (Tan et al., 2020; Wang et al., 2020a). Exosome-integrated bone engineering scaffolds can promote osteogenesis, angiogenesis, and inflammation modulation, which have been applied in various bone defect models, such as critical-sized mouse calvarial defects, mandibular bone defects, femoral condyle defects, and tibia defects in mice, rats, and sheep (Jia et al., 2021; Luo et al., 2019). The details of applications of exosome-integrated bone engineering scaffolds have been summarized in Table 2. In addition, exosome-integrated bone engineering scaffolds promote the recruitment and migration of resident MSCs, the activation of local potential, and the homing ability to the injured sites and newly formed bone tissue sites (Re et al., 2021). For example, Schwann cell–derived exosomes with porous titanium alloy can improve the effects of scaffolds in bone repair (Wu et al., 2020). Ma et al. (2022) reported that hydrogels combined with exosomes and fusion peptides can enhance the therapeutic effect and the retention of exosomes. Yang et al. (2020) revealed that MSC-derived exosomes with injectable hydroxyapatite-embedded in situ cross-linked hyaluronic acid-alginate hydrogel can significantly enhance bone regeneration and retain the exosomes at the defect sites. Although bone engineering scaffolds with exosomes show great potential, there are still some questions to be answered. First, the contents and their functions in exosomes have not yet been illustrated completely, and the effectors of exosomes of different parent sources for bone defect repair are different. Second, the scaffold materials with better osteoconductivity, osteoinduction, osteogenesis, and mechanical support need to be improved. Lastly, the strategies of engineering exosomes, interface modifications, and controlled release in a spatiotemporal manner need to be designed and optimized. To sum up, the progress in materials and engineering technology drives the bone graft substitutes to solve the clinical problems, pointing out the direction of future research studies.
FIGURE 4
TABLE 2
| Source of Exosomes | Isolation method | Scaffold | In vivo model | Effect of exosome-integrated bone engineering scaffolds | References |
|---|---|---|---|---|---|
| Human umbilical cord MSCs | Ultracentrifugation | Coralline hydroxyapatite (CHA)/silk fibroin (SF)/glycol chitosan (GCS)/difunctionalized polyethylene glycol (DF-PEG) self-healing hydrogel | Femoral condyle defect | Pro-bone regeneration and pro-angiogenic activities in vitro and in vivo | Wang et al. (2020a) |
| Human umbilical cord MSCs | Ultracentrifugation | Injectable hydroxyapatite-embedded in situ cross-linked hyaluronic acid-alginate (HA-ALG) hydrogel | Calvarial defect | Pro-bone regeneration activities in vitro and in vivo | Yang et al. (2020) |
| Bone marrow stem cells | Ultracentrifugation | Tannic acid–modified sulfonated polyetheretherketone | Femoral condyle defect | Inflammation modulation and pro-bone regeneration activities in vitro and in vivo | Fan et al. (2021) |
| Human adipose-derived stem cells | Ultracentrifugation | Polydopamine-coating PLGA (PLGA/pDA) scaffolds | Calvarial defect | Pro-bone regeneration activities in vitro and in vivo | Li et al. (2018) |
| MSCs derived from human-induced pluripotent stem cells | Ultracentrifugation | Tricalcium phosphate scaffolds | Calvarial defect | Pro-bone regeneration and pro-angiogenic activities in vitro and in vivo | Qi et al. (2016) |
| MSCs and preosteoblasts | ExoEasy kit | Calcium sulfate-nano-hydroxyapatite nanocement bone filler | Tibia defect | Pro-bone regeneration activities in vitro and in vivo | Teotia et al. (2021) |
| MSCs | Ultracentrifugation | Mesoporous bioactive glass | Calvarial defect | Pro-bone regeneration activities in vitro and in vivo | Liu et al. (2021a) |
| Schwann cells | Ultracentrifugation | Porous Ti6Al4V scaffolds | Femoral condyle defect | Pro-bone regeneration activities in vitro and in vivo | Wu et al. (2020) |
| Human dental pulp stem cells | Ultracentrifugation | Poly(lactic-co-glycolic acid) and poly(ethylene glycol) triblock copolymer microspheres | Calvarial defect | Pro-bone regeneration activities in vitro and in vivo | Swanson et al. (2020) |
| MSCs | ExoQuick-TC kit | 3D-printed titanium alloy scaffolds | Radial bone defect | Pro-bone regeneration activities in vitro and in vivo | Zhai et al. (2020) |
| Chondrogenic progenitor cell line, ATDC5 | Ultracentrifugation | 3D-printed polycaprolactone scaffolds | Radial bone defect | Pro-bone regeneration and pro-angiogenic activities in vitro and in vivo | Zha et al. (2021) |
| Human adipose mesenchymal stem cells | Ultracentrifugation | Hydrogel | Calvarial defect | Pro-bone regeneration activities in vitro and in vivo | Chen et al. (2019) |
| Bone marrow stem cells | Ultracentrifugation | Injectable thermo-sensitive hydrogels | Calvarial defect | Pro-bone regeneration activities in vitro and in vivo | Ma et al. (2022) |
| Umbilical MSCs | Ultracentrifugation | Hyaluronic acid hydrogel | Calvarial defect | Pro-bone regeneration and pro-angiogenic activities in vitro and in vivo | Zhang et al. (2021d) |
| Mature dendritic cells | Ultracentrifugation | Carboxymethyl cellulose-based hydrogel | Femoral bone defect | Pro-bone regeneration activities in vitro and in vivo | Cao et al. (2021) |
| MSCs derived from human-induced pluripotent stem cells | Ultracentrifugation | Tricalcium phosphate scaffolds | Calvarial defect | Pro-bone regeneration activities in vitro and in vivo | Zhang et al. (2016) |
Summary of the applications of exosome-integrated bone engineering scaffolds in bone defects.
Conclusion
The treatment of bone defects is an intractable clinical problem and has attracted great attention around the world. In this review, the current treatments of bone defects and applications of bone engineering scaffolds with exosomes in bone defects are summarized. In addition, the bone defect microenvironment and bone healing mechanism are discussed. In bone defect repair, the supplement of exosomes enhances the effects of bone engineering scaffolds, in which miRNA is one of the important regulators. With the recognition of exosome contents, future patterns of specific miRNA or bioactive molecules with carriers will promote bone regeneration more precisely. Thus, a big step forward would be taken toward the successful treatment of bone defects, delayed union, and non-union.
Statements
Author contributions
LZ, PY, and PT made major contributions to the conception of the work. MZ and YL drafted the manuscript. TF, RL, and ZW participated in the discussion, revised the manuscript, and drew the figures.
Funding
This work was supported by the National Natural Science Foundation of China (Nos. 81972115 and 82002330) and Young Elite Scientist Sponsorship Program by the China Association for Science and Technology (No. 2020-JCJQ-QT-033).
Acknowledgments
The original elements used in the figures are from Servier Medical Art (http://smart.servier.com/).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Al-SowayanB.AlammariF.AlshareedaA. (2020). Preparing the Bone Tissue Regeneration Ground by Exosomes: From Diagnosis to Therapy. Molecules25 (18), 4205. 10.3390/molecules25184205
2
AlfordA. I.NicolaouD.HakeM.McBride‐GagyiS. (2021). Masquelet's Induced Membrane Technique: Review of Current Concepts and Future Directions. J. Orthop. Res.39 (4), 707–718. 10.1002/jor.24978
3
AmiryaghoubiN.FathiM.PesyanN. N.SamieiM.BararJ.OmidiY. (2020). Bioactive Polymeric Scaffolds for Osteogenic Repair and Bone Regenerative Medicine. Med. Res. Rev.40 (5), 1833–1870. 10.1002/med.21672
4
BaldwinP.LiD. J.AustonD. A.MirH. S.YoonR. S.KovalK. J. (2019). Autograft, Allograft, and Bone Graft Substitutes: Clinical Evidence and Indications for Use in the Setting of Orthopaedic Trauma Surgery. J. Orthop. Trauma.33 (4), 203–213. 10.1097/BOT.0000000000001420
5
BharadwazA.JayasuriyaA. C. (2020). Recent Trends in the Application of Widely Used Natural and Synthetic Polymer Nanocomposites in Bone Tissue Regeneration. Mater. Sci. Eng. C110, 110698. 10.1016/j.msec.2020.110698
6
BrennanM. Á.LayrolleP.MooneyD. J. (2020). Biomaterials Functionalized with MSC Secreted Extracellular Vesicles and Soluble Factors for Tissue Regeneration. Adv. Funct. Mat.30 (37), 1909125. 10.1002/adfm.201909125
7
BuckD. W.DumanianG. A. (2012). Bone Biology and Physiology. Plastic Reconstr. Surg.129 (6), 1314–1320. 10.1097/PRS.0b013e31824eca94
8
CaoZ.WuY.YuL.ZouL.YangL.LinS.et al (2021). Exosomal miR-335 Derived from Mature Dendritic Cells Enhanced Mesenchymal Stem Cell-Mediated Bone Regeneration of Bone Defects in Athymic Rats. Mol. Med.27 (1). 10.1186/s10020-021-00268-5
9
ChenS.TangY.LiuY.ZhangP.LvL.ZhangX.et al (2019). Exosomes Derived from miR‐375‐overexpressing Human Adipose Mesenchymal Stem Cells Promote Bone Regeneration. Cell Prolif.52 (5). 10.1111/cpr.12669
10
ChewJ. R. J.ChuahS. J.TeoK. Y. W.ZhangS.LaiR. C.FuJ. H.et al (2019). Mesenchymal Stem Cell Exosomes Enhance Periodontal Ligament Cell Functions and Promote Periodontal Regeneration. Acta Biomater.89, 252–264. 10.1016/j.actbio.2019.03.021
11
CuiY.LuanJ.LiH.ZhouX.HanJ. (2016). Exosomes Derived from Mineralizing Osteoblasts Promote ST2 Cell Osteogenic Differentiation by Alteration of microRNA Expression. FEBS Lett.590 (1), 185–192. 10.1002/1873-3468.12024
12
EbhodagheS. O. (2021). Natural Polymeric Scaffolds for Tissue Engineering Applications. J. Biomaterials Sci. Polym. Ed.32 (16), 2144–2194. 10.1080/09205063.2021.1958185
13
ElliottD. S.NewmanK. J. H.ForwardD. P.HahnD. M.OllivereB.KojimaK.et al (2016). A Unified Theory of Bone Healing and Nonunion. Bone & Jt. J.98-B (7), 884–891. 10.1302/0301-620X.98B7.36061
14
Escudé Martinez de CastillaP.TongL.HuangC.SofiasA. M.PastorinG.ChenX.et al (2021). Extracellular Vesicles as a Drug Delivery System: A Systematic Review of Preclinical Studies. Adv. Drug Deliv. Rev.175, 113801. 10.1016/j.addr.2021.05.011
15
FanJ.LeeC.-S.KimS.ChenC.AghalooT.LeeM. (2020). Generation of Small RNA-Modulated Exosome Mimetics for Bone Regeneration. ACS Nano14 (9), 11973–11984. 10.1021/acsnano.0c05122
16
FanL.GuanP.XiaoC.WenH.WangQ.LiuC.et al (2021). Exosome-functionalized Polyetheretherketone-Based Implant with Immunomodulatory Property for Enhancing Osseointegration. Bioact. Mater.6 (9), 2754–2766. 10.1016/j.bioactmat.2021.02.005
17
FurutaT.MiyakiS.IshitobiH.OguraT.KatoY.KameiN.et al (2016). Mesenchymal Stem Cell-Derived Exosomes Promote Fracture Healing in a Mouse Model. Stem Cells Transl. Med.5 (12), 1620–1630. 10.5966/sctm.2015-0285
18
GandolfiM. G.GardinC.ZampariniF.FerroniL.EspostiM. D.ParchiG.et al (2020). Mineral-doped Poly(L-Lactide) Acid Scaffolds Enriched with Exosomes Improve Osteogenic Commitment of Human Adipose-Derived Mesenchymal Stem Cells. Nanomaterials10 (3), 432. 10.3390/nano10030432
19
GaoC.DengY.FengP.MaoZ.LiP.YangB.et al (2014). Current Progress in Bioactive Ceramic Scaffolds for Bone Repair and Regeneration. Ijms15 (3), 4714–4732. 10.3390/ijms15034714
20
GuanP.LiuC.XieD.MaoS.JiY.LinY.et al (2022). Exosome-loaded Extracellular Matrix-Mimic Hydrogel with Anti-inflammatory Property Facilitates/promotes Growth Plate Injury Repair. Bioact. Mater.10, 145–158. 10.1016/j.bioactmat.2021.09.010
21
HaoJ.BaiB.CiZ.TangJ.HuG.DaiC.et al (2022). Large-sized Bone Defect Repair by Combining a Decalcified Bone Matrix Framework and Bone Regeneration Units Based on Photo-Crosslinkable Osteogenic Microgels. Bioact. Mater.14, 97–109. 10.1016/j.bioactmat.2021.12.013
22
HuH.DongL.BuZ.ShenY.LuoJ.ZhangH.et al (2020). miR‐23a‐3p‐abundant Small Extracellular Vesicles Released from Gelma/nanoclay Hydrogel for Cartilage Regeneration. J. Extracell. Vesicles9 (1), 1778883. 10.1080/20013078.2020.1778883
23
HuberJ.GriffinM. F.LongakerM. T.QuartoN. (2022). Exosomes: A Tool for Bone Tissue Engineering. Tissue Eng. Part B Rev.28 (1), 101–113. 10.1089/ten.teb.2020.0246
24
JiaB.YangH.ZhangZ.QuX.JiaX.WuQ.et al (2021). Biodegradable Zn-Sr Alloy for Bone Regeneration in Rat Femoral Condyle Defect Model: In Vitro and In Vivo Studies. Bioact. Mater.6 (6), 1588–1604. 10.1016/j.bioactmat.2020.11.007
25
JiangS.TianG.YangZ.GaoX.WangF.LiJ.et al (2021). Enhancement of Acellular Cartilage Matrix Scaffold by Wharton's Jelly Mesenchymal Stem Cell-Derived Exosomes to Promote Osteochondral Regeneration. Bioact. Mater.6 (9), 2711–2728. 10.1016/j.bioactmat.2021.01.031
26
JingX.WangS.TangH.LiD.ZhouF.XinL.et al (2022). Dynamically Bioresponsive DNA Hydrogel Incorporated with Dual-Functional Stem Cells from Apical Papilla-Derived Exosomes Promotes Diabetic Bone Regeneration. ACS Appl. Mat. Interfaces14, 16082–16099. 10.1021/acsami.2c02278
27
JulienA.KanagalingamA.Martínez-SarràE.MegretJ.LukaM.MénagerM.et al (2021). Direct Contribution of Skeletal Muscle Mesenchymal Progenitors to Bone Repair. Nat. Commun.12 (1). 10.1038/s41467-021-22842-5
28
KalfasI. H. (2001). Principles of Bone Healing. Foc10 (4), 1–4. 10.3171/foc.2001.10.4.2
29
LiD.LiuJ.GuoB.LiangC.DangL.LuC.et al (2016). Osteoclast-derived Exosomal miR-214-3p Inhibits Osteoblastic Bone Formation. Nat. Commun.7 (1). 10.1038/ncomms10872
30
LiF.WuJ.LiD.HaoL.LiY.YiD.et al (2022). Engineering Stem Cells to Produce Exosomes with Enhanced Bone Regeneration Effects: An Alternative Strategy for Gene Therapy. J. Nanobiotechnol.20 (1). 10.1186/s12951-022-01347-3
31
LiL.LuH.ZhaoY.LuoJ.YangL.LiuW.et al (2019). Functionalized Cell-free Scaffolds for Bone Defect Repair Inspired by Self-Healing of Bone Fractures: A Review and New Perspectives. Mater. Sci. Eng. C98, 1241–1251. 10.1016/j.msec.2019.01.075
32
LiS.LiuY.TianT.ZhangT.LinS.ZhouM.et al (2021a). Bioswitchable Delivery of microRNA by Framework Nucleic Acids: Application to Bone Regeneration. Small17 (47), 2104359. 10.1002/smll.202104359
33
LiW.LiuY.ZhangP.TangY.ZhouM.JiangW.et al (2018). Tissue-Engineered Bone Immobilized with Human Adipose Stem Cells-Derived Exosomes Promotes Bone Regeneration. ACS Appl. Mat. Interfaces10 (6), 5240–5254. 10.1021/acsami.7b17620
34
LiY.ChenM.ZhaoY.LiM.QinY.ChengS.et al (2020). Advance in Drug Delivery for Ageing Skeletal Muscle. Front. Pharmacol.11. 10.3389/fphar.2020.01016
35
LiZ.ZhangX.OuyangJ.ChuD.HanF.ShiL.et al (2021b). Ca2+-supplying Black Phosphorus-Based Scaffolds Fabricated with Microfluidic Technology for Osteogenesis. Bioact. Mater.6 (11), 4053–4064. 10.1016/j.bioactmat.2021.04.014
36
LinZ.XiongY.MengW.HuY.ChenL.ChenL.et al (2022). Exosomal PD-L1 Induces Osteogenic Differentiation and Promotes Fracture Healing by Acting as an Immunosuppressant. Bioact. Mater.13, 300–311. 10.1016/j.bioactmat.2021.10.042
37
LiuA.LinD.ZhaoH.ChenL.CaiB.LinK.et al (2021a). Optimized BMSC-Derived Osteoinductive Exosomes Immobilized in Hierarchical Scaffold via Lyophilization for Bone Repair through Bmpr2/Acvr2b Competitive Receptor-Activated Smad Pathway. Biomaterials272, 120718. 10.1016/j.biomaterials.2021.120718
38
LiuM.SunY.ZhangQ. (2018). Emerging Role of Extracellular Vesicles in Bone Remodeling. J. Dent. Res.97 (8), 859–868. 10.1177/0022034518764411
39
LiuW.-z.MaZ.-j.LiJ.-r.KangX.-w. (2021b). Mesenchymal Stem Cell-Derived Exosomes: Therapeutic Opportunities and Challenges for Spinal Cord Injury. Stem Cell Res. Ther.12 (1), 102. 10.1186/s13287-021-02153-8
40
LiuW.LiL.RongY.QianD.ChenJ.ZhouZ.et al (2020). Hypoxic Mesenchymal Stem Cell-Derived Exosomes Promote Bone Fracture Healing by the Transfer of miR-126. Acta Biomater.103, 196–212. 10.1016/j.actbio.2019.12.020
41
LuH.ZhangY.XiongS.ZhouY.XiaoL.MaY.et al (2021). Modulatory Role of Silver Nanoparticles and Mesenchymal Stem Cell-Derived Exosome-Modified Barrier Membrane on Macrophages and Osteogenesis. Front. Chem.9. 10.3389/fchem.2021.699802
42
LuJ.WangQ.-Y.ShengJ.-G. (2019). Exosomes in the Repair of Bone Defects: Next-Generation Therapeutic Tools for the Treatment of Nonunion. BioMed Res. Int.2019, 1–11. 10.1155/2019/1983131
43
LuoZ.-W.LiF.-X. -Z.LiuY.-W.RaoS.-S.YinH.HuangJ.et al (2019). Aptamer-functionalized Exosomes from Bone Marrow Stromal Cells Target Bone to Promote Bone Regeneration. Nanoscale11 (43), 20884–20892. 10.1039/C9NR02791B
44
MaL.WangX.ZhouY.JiX.ChengS.BianD.et al (2021). Biomimetic Ti-6Al-4V Alloy/gelatin Methacrylate Hybrid Scaffold with Enhanced Osteogenic and Angiogenic Capabilities for Large Bone Defect Restoration. Bioact. Mater.6 (10), 3437–3448. 10.1016/j.bioactmat.2021.03.010
45
MaS.WuJ.HuH.MuY.ZhangL.ZhaoY.et al (2022). Novel Fusion Peptides Deliver Exosomes to Modify Injectable Thermo-Sensitive Hydrogels for Bone Regeneration. Mater. Today Bio13, 100195. 10.1016/j.mtbio.2021.100195
46
MackieE. J.TatarczuchL.MiramsM. (2011). The Skeleton: A Multi-Functional Complex Organ. The Growth Plate Chondrocyte and Endochondral Ossification. J. Endocrinol.211 (2), 109–121. 10.1530/JOE-11-0048
47
MajidiniaM.SadeghpourA.YousefiB. (2018). The Roles of Signaling Pathways in Bone Repair and Regeneration. J. Cell. Physiol.233 (4), 2937–2948. 10.1002/jcp.26042
48
MorelliI.DragoL.GeorgeD. A.GallazziE.ScarponiS.RomanòC. L. (2016). Masquelet Technique: Myth or Reality? A Systematic Review and Meta-Analysis. Injury47, S68–S76. 10.1016/S0020-1383(16)30842-7
49
NarayananR.HuangC.-C.RavindranS. (2016). Hijacking the Cellular Mail: Exosome Mediated Differentiation of Mesenchymal Stem Cells. Stem Cells Int.2016, 1–11. 10.1155/2016/3808674
50
NauthA.SchemitschE.NorrisB.NollinZ.WatsonJ. T. (2018). Critical-Size Bone Defects: Is There a Consensus for Diagnosis and Treatment?J. Orthop. Trauma.32 (3), S7–S11. 10.1097/BOT.0000000000001115
51
NicholsonJ.MakaramN.SimpsonA.KeatingJ. (2021). Fracture Nonunion in Long Bones: A Literature Review of Risk Factors and Surgical Management. Injury52, S3–S11. 10.1016/j.injury.2020.11.029
52
NikhilA.KumarA. (2022). Evaluating Potential of Tissue‐engineered Cryogels and Chondrocyte Derived Exosomes in Articular Cartilage Repair. Biotech Bioeng.119 (2), 605–625. 10.1002/bit.27982
53
OftadehR.Perez-ViloriaM.Villa-CamachoJ. C.VaziriA.NazarianA. (2015). Biomechanics and Mechanobiology of Trabecular Bone: A Review. J. Biomech. Eng.137 (1). 10.1115/1.4029176
54
OryanA.MonazzahS.Bigham-SadeghA. (2015). Bone Injury and Fracture Healing Biology. Biomed. Environ. Sci.28 (1), 57–71. 10.3967/bes2015.006
55
PercivalC. J.RichtsmeierJ. T. (2013). Angiogenesis and Intramembranous Osteogenesis. Dev. Dyn.242 (8), 909–922. 10.1002/dvdy.23992
56
PishavarE.LuoH.NaserifarM.HashemiM.ToosiS.AtalaA.et al (2021). Advanced Hydrogels as Exosome Delivery Systems for Osteogenic Differentiation of MSCs: Application in Bone Regeneration. Ijms22 (12), 6203. 10.3390/ijms22126203
57
QiX.ZhangJ.YuanH.XuZ.LiQ.NiuX.et al (2016). Exosomes Secreted by Human-Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Repair Critical-Sized Bone Defects through Enhanced Angiogenesis and Osteogenesis in Osteoporotic Rats. Int. J. Biol. Sci.12 (7), 836–849. 10.7150/ijbs.14809
58
QinY.SunR.WuC.WangL.ZhangC. (2016). Exosome: A Novel Approach to Stimulate Bone Regeneration through Regulation of Osteogenesis and Angiogenesis. Ijms17 (5), 712. 10.3390/ijms17050712
59
RamisJ. M. (2020). Extracellular Vesicles in Cell Biology and Medicine. Sci. Rep.10 (1). 10.1038/s41598-020-65826-z
60
ReF.GabusiE.ManferdiniC.RussoD.LisignoliG. (2021). Bone Regeneration Improves with Mesenchymal Stem Cell Derived Extracellular Vesicles (EVs) Combined with Scaffolds: A Systematic Review. Biology10 (7), 579. 10.3390/biology10070579
61
RosetiL.ParisiV.PetrettaM.CavalloC.DesandoG.BartolottiI.et al (2017). Scaffolds for Bone Tissue Engineering: State of the Art and New Perspectives. Mater. Sci. Eng. C78, 1246–1262. 10.1016/j.msec.2017.05.017
62
SafariB.DavaranS.AghanejadA. (2021). Osteogenic Potential of the Growth Factors and Bioactive Molecules in Bone Regeneration. Int. J. Biol. Macromol.175, 544–557. 10.1016/j.ijbiomac.2021.02.052
63
SahooS.KlychkoE.ThorneT.MisenerS.SchultzK. M.MillayM.et al (2011). Exosomes from Human CD34 + Stem Cells Mediate Their Proangiogenic Paracrine Activity. Circ. Res.109 (7), 724–728. 10.1161/CIRCRESAHA.111.253286
64
SchmidtA. H. (2021). Autologous Bone Graft: Is it Still the Gold Standard?Injury52, S18–S22. 10.1016/j.injury.2021.01.043
65
ShangF.YuY.LiuS.MingL.ZhangY.ZhouZ.et al (2021). Advancing Application of Mesenchymal Stem Cell-Based Bone Tissue Regeneration. Bioact. Mater.6 (3), 666–683. 10.1016/j.bioactmat.2020.08.014
66
ShenK.DuanA.ChengJ.YuanT.ZhouJ.SongH.et al (2022). Exosomes Derived from Hypoxia Preconditioned Mesenchymal Stem Cells Laden in a Silk Hydrogel Promote Cartilage Regeneration via the miR-205-5p/PTEN/AKT Pathway. Acta Biomater.143, 173–188. 10.1016/j.actbio.2022.02.026
67
SwansonW. B.ZhangZ.XiuK.GongT.EberleM.WangZ.et al (2020). Scaffolds with Controlled Release of Pro-mineralization Exosomes to Promote Craniofacial Bone Healing without Cell Transplantation. Acta Biomater.118, 215–232. 10.1016/j.actbio.2020.09.052
68
TanB.TangQ.ZhongY.WeiY.HeL.WuY.et al (2021). Biomaterial-based Strategies for Maxillofacial Tumour Therapy and Bone Defect Regeneration. Int. J. Oral Sci.13 (1), 9. 10.1038/s41368-021-00113-9
69
TanS. H. S.WongJ. R. Y.SimS. J. Y.TjioC. K. E.WongK. L.ChewJ. R. J.et al (2020). Mesenchymal Stem Cell Exosomes in Bone Regenerative Strategies-A Systematic Review of Preclinical Studies. Mater. Today Bio7, 100067. 10.1016/j.mtbio.2020.100067
70
TeotiaA. K.QayoomI.SinghP.MishraA.JaimanD.SeppäläJ.et al (2021). Exosome-Functionalized Ceramic Bone Substitute Promotes Critical-Sized Bone Defect Repair in Rats. ACS Appl. Bio Mat.4 (4), 3716–3726. 10.1021/acsabm.1c00311
71
TovarN.WitekL.AtriaP.SobierajM.BowersM.LopezC. D.et al (2018). Form and Functional Repair of Long Bone Using 3D‐printed Bioactive Scaffolds. J. Tissue Eng. Regen. Med.12 (9), 1986–1999. 10.1002/term.2733
72
TurnbullG.ClarkeJ.PicardF.RichesP.JiaL.HanF.et al (2018). 3D Bioactive Composite Scaffolds for Bone Tissue Engineering. Bioact. Mater.3 (3), 278–314. 10.1016/j.bioactmat.2017.10.001
73
WangL.WangJ.ZhouX.SunJ.ZhuB.DuanC.et al (2020a). A New Self-Healing Hydrogel Containing hucMSC-Derived Exosomes Promotes Bone Regeneration. Front. Bioeng. Biotechnol.8. 10.3389/fbioe.2020.564731
74
WangW.YeungK. W. K. (2017). Bone Grafts and Biomaterials Substitutes for Bone Defect Repair: A Review. Bioact. Mater.2 (4), 224–247. 10.1016/j.bioactmat.2017.05.007
75
WangX.AoJ.LuH.ZhaoQ.MaY.ZhangJ.et al (2020b). Osteoimmune Modulation and Guided Osteogenesis Promoted by Barrier Membranes Incorporated with S-Nitrosoglutathione (GSNO) and Mesenchymal Stem Cell-Derived Exosomes. Ijn15, 3483–3496. 10.2147/IJN.S248741<
76
WangX.YuY.YangC.ShaoC.ShiK.ShangL.et al (2021). Microfluidic 3D Printing Responsive Scaffolds with Biomimetic Enrichment Channels for Bone Regeneration. Adv. Funct. Mater.31 (40), 2105190. 10.1002/adfm.202105190
77
WatanabeY.TsuchiyaA.TeraiS. (2021). The Development of Mesenchymal Stem Cell Therapy in the Present, and the Perspective of Cell-free Therapy in the Future. Clin. Mol. Hepatol.27 (1), 70–80. 10.3350/cmh.2020.0194
78
WeiF.LiM.CrawfordR.ZhouY.XiaoY. (2019). Exosome-integrated Titanium Oxide Nanotubes for Targeted Bone Regeneration. Acta Biomater.86, 480–492. 10.1016/j.actbio.2019.01.006
79
WeilnerS.KeiderV.WinterM.HarreitherE.SalzerB.WeissF.et al (2016). Vesicular Galectin-3 Levels Decrease with Donor Age and Contribute to the Reduced Osteo-Inductive Potential of Human Plasma Derived Extracellular Vesicles. Aging8 (1), 16–30. 10.18632/aging.100865
80
WieseA.PapeH. C. (2010). Bone Defects Caused by High-Energy Injuries, Bone Loss, Infected Nonunions, and Nonunions. Orthop. Clin. N. Am.41 (1), 1–4. 10.1016/j.ocl.2009.07.003
81
WuD.ChangX.TianJ.KangL.WuY.LiuJ.et al (2021). Bone Mesenchymal Stem Cells Stimulation by Magnetic Nanoparticles and a Static Magnetic Field: Release of Exosomal miR-1260a Improves Osteogenesis and Angiogenesis. J. Nanobiotechnol.19 (1). 10.1186/s12951-021-00958-6
82
WuD.QinH.WangZ.YuM.LiuZ.PengH.et al (2022). Bone Mesenchymal Stem Cell-Derived sEV-Encapsulated Thermosensitive Hydrogels Accelerate Osteogenesis and Angiogenesis by Release of Exosomal miR-21. Front. Bioeng. Biotechnol.9. 10.3389/fbioe.2021.829136
83
WuZ.PuP.SuZ.ZhangX.NieL.ChangY. (2020). Schwann Cell-Derived Exosomes Promote Bone Regeneration and Repair by Enhancing the Biological Activity of Porous Ti6Al4V Scaffolds. Biochem. Biophysical Res. Commun.531 (4), 559–565. 10.1016/j.bbrc.2020.07.094
84
YangS.ZhuB.YinP.ZhaoL.WangY.FuZ.et al (2020). Integration of Human Umbilical Cord Mesenchymal Stem Cells-Derived Exosomes with Hydroxyapatite-Embedded Hyaluronic Acid-Alginate Hydrogel for Bone Regeneration. ACS Biomater. Sci. Eng.6 (3), 1590–1602. 10.1021/acsbiomaterials.9b01363
85
YinB.MaQ.SongC.ZhaoL.YuF.WangC.et al (2021). Exosome-Derived Noncoding RNAs as a Promising Treatment of Bone Regeneration. Stem Cells Int.2021, 1–8. 10.1155/2021/6696894
86
YuW.LiS.GuanX.ZhangN.XieX.ZhangK.et al (2022). Higher Yield and Enhanced Therapeutic Effects of Exosomes Derived from MSCs in Hydrogel-Assisted 3D Culture System for Bone Regeneration. Mater. Sci. Eng. C, 112646. 10.1016/j.msec.2022.112646
87
ZhaY.LiY.LinT.ChenJ.ZhangS.WangJ. (2021). Progenitor Cell-Derived Exosomes Endowed with VEGF Plasmids Enhance Osteogenic Induction and Vascular Remodeling in Large Segmental Bone Defects. Theranostics11 (1), 397–409. 10.7150/thno.50741
88
ZhaiM.ZhuY.YangM.MaoC. (2020). Human Mesenchymal Stem Cell Derived Exosomes Enhance Cell‐Free Bone Regeneration by Altering Their miRNAs Profiles. Adv. Sci.7 (19), 2001334. 10.1002/advs.202001334
89
ZhangB.HuangJ.LiuJ.LinF.DingZ.XuJ. (2021a). Injectable Composite Hydrogel Promotes Osteogenesis and Angiogenesis in Spinal Fusion by Optimizing the Bone Marrow Mesenchymal Stem Cell Microenvironment and Exosomes Secretion. Mater. Sci. Eng. C123, 111782. 10.1016/j.msec.2020.111782
90
ZhangH.WangR.WangG.ZhangB.WangC.LiD.et al (2021b). Single-Cell RNA Sequencing Reveals B Cells Are Important Regulators in Fracture Healing. Front. Endocrinol.12. 10.3389/fendo.2021.666140
91
ZhangJ.JiangY.ShangZ.ZhaoB.JiaoM.LiuW.et al (2021c). Biodegradable Metals for Bone Defect Repair: A Systematic Review and Meta-Analysis Based on Animal Studies. Bioact. Mater.6 (11), 4027–4052. 10.1016/j.bioactmat.2021.03.035
92
ZhangJ.LiuX.LiH.ChenC.HuB.NiuX.et al (2016). Exosomes/tricalcium Phosphate Combination Scaffolds Can Enhance Bone Regeneration by Activating the PI3K/Akt Signaling Pathway. Stem Cell Res. Ther.7 (1). 10.1186/s13287-016-0391-3
93
ZhangT.TianT.LinY. (2022). Functionalizing Framework Nucleic‐Acid‐Based Nanostructures for Biomedical Application. Adv. Mater., 2107820. 10.1002/adma.202107820
94
ZhangY.ChenY.KouH.YangP.WangY.LuT. (2018). Enhanced Bone Healing in Porous Ti Implanted Rabbit Combining Bioactive Modification and Mechanical Stimulation. J. Mech. Behav. Biomed. Mater.86, 336–344. 10.1016/j.jmbbm.2018.06.042
95
ZhangY.XieY.HaoZ.ZhouP.WangP.FangS.et al (2021d). Umbilical Mesenchymal Stem Cell-Derived Exosome-Encapsulated Hydrogels Accelerate Bone Repair by Enhancing Angiogenesis. ACS Appl. Mat. Interfaces13 (16), 18472–18487. 10.1021/acsami.0c22671
96
ZhouP.XiaD.NiZ.OuT.WangY.ZhangH.et al (2021). Calcium Silicate Bioactive Ceramics Induce Osteogenesis through Oncostatin M. Bioact. Mater.6 (3), 810–822. 10.1016/j.bioactmat.2020.09.018
97
ZhuG.ZhangT.ChenM.YaoK.HuangX.ZhangB.et al (2021). Bone Physiological Microenvironment and Healing Mechanism: Basis for Future Bone-Tissue Engineering Scaffolds. Bioact. Mater.6 (11), 4110–4140. 10.1016/j.bioactmat.2021.03.043
Summary
Keywords
bone tissue engineering, scaffold, bone defect, bone regeneration, cell-free therapy, exosome
Citation
Zhang M, Li Y, Feng T, Li R, Wang Z, Zhang L, Yin P and Tang P (2022) Bone Engineering Scaffolds With Exosomes: A Promising Strategy for Bone Defects Repair. Front. Bioeng. Biotechnol. 10:920378. doi: 10.3389/fbioe.2022.920378
Received
14 April 2022
Accepted
06 May 2022
Published
15 June 2022
Volume
10 - 2022
Edited by
Jianxun Ding, Changchun Institute of Applied Chemistry (CAS), China
Reviewed by
Xiaoxiao Cai, Sichuan University, China
Lei Sui, Tianjin Medical University, China
Updates
Copyright
© 2022 Zhang, Li, Feng, Li, Wang, Zhang, Yin and Tang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Licheng Zhang, zhanglcheng218@126.com; Pengbin Yin, yinpengbin@gmail.com
†These authors have contributed equally to this work
This article was submitted to Biomaterials, a section of the journal Frontiers in Bioengineering and Biotechnology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.